A vaccine against the corona virus from Oxford University and pharmaceutical company AstraZeneca could be ready by next month.
AstraZeneca’s chief executive said his corona virus vaccine would be ready for use by the end of December, awaiting regulatory approval.
Read More:‘Early cod vaccines will not prevent the epidemic’
In an interview with a Swedish newspaper, Chief Executive Pascal Soroit said: “Regulatory authorities are constantly working on our data. If they are ready to act swiftly when we are ready, we will have people by the end of January or December.” We will start providing vaccines.
The vaccine from Oxford University and AstraZeneca is being hailed as one of the best efforts to treat the corona virus, which has been in the works for months.
“Although we will never be able to make money from this vaccine, no one still knows how long people will need to be vaccinated, if this vaccine is very effective and people are protected for many years,” said Pascal Suryot. If the disease disappears, then there will be no market for it.
However, he said that most experts believe that people will need the vaccine again, if this happens on an annual basis, we will start earning revenue from this vaccine in 2022.
“But first we have to believe that the vaccine is really effective,” he added.
The Oxford University vaccine entered the third phase of the trial in September, during which the trial was temporarily suspended in some countries due to some concerns.
The European Union, the United States, the United Kingdom, Japan and Brazil have signed preliminary agreements with AstraZeneca to obtain the vaccine once it is approved.
Read More:Volunteer dies during coronavirus vaccine trial in Brazil
Leon Wang, head of the company in China, said the vaccine was expected to be approved in China by mid-2021, depending on data on its safety in the first and second phases of the trial and its usefulness in the third phase. Will be on the data.
He said the help of a local partner would be sought for vaccine trials in China.
The trial of the Code 19 vaccine, developed under the auspices of the University of Oxford in the United Kingdom, began in April.
The trial at the Oxford University vaccine is in its final stages and was previously said to be ready by September, but could now be introduced in late December or early January.
Oxford University has promised to provide its vaccine worldwide at 3 3 per dose.
The British university has already partnered with Swedish-based pharmaceutical company AstraZenka to develop dosage doses of the vaccine, and various organizations such as the Serum Institute of India (SII), Coalition The Epidemic Prevention Innovation (CEPI) and GAVI Vaccine Alliance have also been merged.
Read More:China’s experimental Corona vaccine declared safe in third phase
The Bill & Melinda Gates Foundation, the founding charity of Microsoft, has announced 750 million for the Code 19 vaccine being developed under Oxford University in the United Kingdom.